This review is an update of a 2021 Product Review of osimertinib (Tagrisso®), a third-generation epidermal growth factor receptor tyrosine kinase inhibitor, in the treatment of non-small cell lung cancer, following additional indication approvals and changes to reimbursement. New data from more recently published pivotal clinical trials and from follow-up analyses of earlier trials have been added as well as consideration of liquid biopsy for mutation status testing.
Please login below to download this issue (PDF)